COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,046 Articles (22,627 medRxiv, 8,419 bioRxiv)

Most recent first Previous |  Page 914: Articles 9131-9140  | Next

Safety and Efficacy of Preventative COVID Vaccines: The StopCoV Study
Walmsley, S., Szadkowski, L., Wouters, B., Clarke, R., Colwill, K., Rochon, P., Brudno, M., Ravindran, R., Raboud, J., McGeer, A., Oza, A., Graham, C., Silva, A., Manase, D., Parente, L., Simpson, J., Dayam, R. M., Pasculescu, A., Gingras, A.-C.
10.1101/2022.02.09.22270734 — Posted: 2022-02-10
Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir
Singh, R. S. P., Toussi, S. S., Hackman, F., Chan, P. L., Rao, R., Allen, R., Van Eyck, L., Pawlak, S., Kadar, E. P., Clark, F., Shi, H., Anderson, A. S., Binks, M., Menon, S., Nucci, G., Bergman, A.
10.1101/2022.02.08.22270649 — Posted: 2022-02-10
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico
Ponce-de-Leon, S., Torres, M., Soto-Ramirez, L. E., Calva, J. J., Santillan-Doherty, P., Carranza-Salazar, D. E., Carreno, J. M., Carranza, C., Juarez, E., Carreto-Binaghi, L. E., Ramirez-Martinez, L., Paz-De la Rosa, G., Vigueras-Moreno, R., Ortiz-Stern, A., Lopez-Vidal, Y., Macias, A. E., Torres-Flores, J., Rojas-Martinez, O., Suarez-Martinez, A., Peralta-Sanchez, G., Kawabata, H., Gonzalez-Dominguez, I., Martinez-Guevara, J. L., Sun, W., Sarfati-Mizrahi, D., Soto-Priante, E., Chagoya-Cortes, H. E., Lopez-Macias, C., Castro-Peralta, F., Palese, P., Garcia-Sastre, A., Krammer, F., Lozano-Dubernard, B.
10.1101/2022.02.08.22270676 — Posted: 2022-02-09
DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study
DiIorio, M., Cook, C. E., Vanni, K. M. M., Patel, N. J., D'Silva, K. M., Fu, X., Wang, J., Prisco, L. C., Kowalski, E., Zaccardelli, A., Martin, L. W., Qian, G., Hsu, T. Y.- T., Wallace, Z. S., Sparks, J. A.
10.1101/2022.02.08.22270696 — Posted: 2022-02-09
Sero-prevalence of anti-SARS-CoV-2 antibodies in Chattogram Metropolitan Area, Bangladesh
Ara, J., Islam, M. S., Kader, M. T. U., Das, A., Hasib, F. M. Y., Islam, M. S., Rahman, T., Das, S., Chowdhury, M. A. H., Das, G. B., Chowdhury, S.
10.1101/2022.02.09.22270717 — Posted: 2022-02-09
Estimation of COVID-19 cases prevented by vaccination in California
Tan, S., Park, H., Rodriguez-Barraquer, I., Rutherford, G. W., Bibbins-Domingo, K., Schechter, R., Lo, N. C.
10.1101/2022.02.08.22269319 — Posted: 2022-02-09
Where is Omicron? Comparison of SARS-CoV-2 RT-PCR and Antigen Test Sensitivity at Commonly Sampled Anatomic Sites Over the Course of Disease
Lin, J., Frediani, J. K., Damhorst, G. L., Sullivan, J. A., Westbrook, A., McLendon, K., Baugh, T. J., O'Sick, W. H., Roback, J. D., Piantadosi, A. L., Waggoner, J. J., Rao, A., Bassit, L. C., Greenleaf, M., O'Neal, J. W., Swanson, S., Pollock, N. R., Martin, G. S., Lam, W. A., Levy, J. M.
10.1101/2022.02.08.22270685 — Posted: 2022-02-09
Trajectories of Neurological Recovery 12 Months after Hospitalization for COVID-19: A Prospective Longitudinal Study
Frontera, J. A., Yang, D., medircherla, C., baskharoun, s., bauman, k., Bell, L., bhagat, d., bondi, s., chervinsky, a., dygert, l., fuchs, b., gratch, d., hasanaj, l., horng, j., huang, j., jauregui, r., Ji, Y., Kahn, E., koch, e., Lin, J., liu, s., olivera, a., rosenthal, j., snyder, t., stainman, r., talmasov, d., thomas, b., valdes, e., Zhou, T., zhu, y., lewis, a., lord, a., melmed, k., meropol, s., thawani, s., troxel, a., yaghi, s., balcer, l., wisniewski, t., Galetta, S.
10.1101/2022.02.08.22270674 — Posted: 2022-02-09
Increasing viral transmission paradoxically reduces progression rates to severe COVID-19 during endemic transition
Hong, H., Noh, J. Y., Lee, H., Choi, S., Choi, B., Kim, J. K., Shin, E.-C.
10.1101/2022.02.09.22270633 — Posted: 2022-02-09 Discussion: Onsite
Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial
Ishmukhametov, A. A., Siniugina, A. A., Yagovkina, N. V., Kuzubov, V. I., Zakharov, K. A., Volok, V. P., Dodina, M. S., Gmyl, L. V., Korotina, N. A., Theodorovich, R. D., Ulitina, Y. I., Tsaan, A. A., Pomaskina, T. V., Kalenskaya, A. V., Solovjeva, I. V., Tivanova, E. V., Kondrasheva, L. Y., Ploskireva, A. A., Akimkin, V. G., Subbotina, K. A., Ignatyev, G. M., Korduban, A. K., Shustova, E. Y., Bayurova, E. O., Kondrashova, A. S., Avdoshina, D. V., Piniaeva, A. N., Kovpak, A. A., Antonova, L. P., Rogova, Y. V., Shishova, A. A., Ivin, Y. Y., Sotskova, S. E., Chernov, K. A., Ipatova, E. G., Korduban, E. A., Kozlovskaya, L. I., Gordeychuk, I. V.
10.1101/2022.02.08.22270658 — Posted: 2022-02-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).